Brain tumor survival at one hospital in Morocco
Original title: Clinicopathological characteristics and prognostic factors of diffuse infiltrating glioma in Morocco: A retrospective single-center institutional experience under the 2021 WHO classification.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a look back at patient records, not a test of a new treatment.
The short version
People who got the full course of treatment lived longer than those who did not.
What was studied. Doctors looked back at the records of 122 people treated for a brain tumor called diffuse glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary. All were treated at one cancer center in Casablanca, Morocco.
What they found. 75% of these tumors were glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. For the 64 people with glioblastoma, the typical survival time was 9 months, and 27% were still alive 2 years later. Younger people did better, and so did people who got the full set of treatments. Treatment was the one factor that mattered on its own.
What this means, and what it doesn't
What it could mean: How much treatment a person got made a real difference here. People who received the full course lived about as long as people in reports from other countries. It may help to ask your care team what a full course of treatment would look like for you.
What it doesn't mean: This is not a new drug or a new therapy, and it is not a promise of a cure. It is a look back at old records from one hospital in one country. Nothing new was tested. These numbers describe a group of people, not any one person, and your own situation may be very different.
Source: PubMed, August 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.